Metabolomics comparison between Delta and Omicron-infected individuals
dc.contributor.advisor | Winston, Brent | |
dc.contributor.advisor | Lee, Chel | |
dc.contributor.author | Pimentel Guerrero, Eric Iván | |
dc.contributor.committeemember | Habibi, Hamid | |
dc.contributor.committeemember | McDonald, Braedon | |
dc.date | 2025-02 | |
dc.date.accessioned | 2025-01-07T20:27:15Z | |
dc.date.available | 2025-01-07T20:27:15Z | |
dc.date.issued | 2025-01-06 | |
dc.description.abstract | At the end of 2019, SARS-CoV-2, the novel coronavirus emerged causing a widespread increase in airway and lung infections that was driven by different viral variants. Only the variants with significant differences in transmissibility, disease severity, reduction in neutralization by antibodies, and reduction in treatment effectiveness were designated as variants of concern (VOC). Among these variants, the Delta and Omicron forms have demonstrated marked differences in transmissibility and disease severity. This study aims to identify the plasma metabolomics differences that characterize Delta-infected compared to Omicron-infected patients, analyze the severity within these SARS-CoV-2 variant infections, and investigate how vaccination status and corticosteroid treatment impacted the plasma metabolomic profiles of these patients infected with these variants. Our hypothesis is that the metabolomic profiles will reveal significant metabolomic differences between the two variants, reflecting their varied clinical outcomes. Furthermore, we hypothesize that the treatments used during each variant’s wave of infection may be reflected in the plasma metabolome of infected individuals. This study demonstrates that not only are there differences in plasma metabolites that distinguish Delta and Omicron-infected individuals, but also that metabolites do differentiate between various degrees of severity. | |
dc.identifier.citation | Pimentel Guerrero, E. I. (YYYY). Metabolomics comparison between delta and omicron-infected individuals (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. | |
dc.identifier.uri | https://hdl.handle.net/1880/120373 | |
dc.language.iso | en | |
dc.publisher.faculty | Graduate Studies | |
dc.publisher.institution | University of Calgary | |
dc.rights | University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission. | |
dc.subject | SARS-CoV-2 | |
dc.subject | COVID-19 | |
dc.subject | Delta | |
dc.subject | Omicron | |
dc.subject | Metabolomics | |
dc.subject.classification | Biochemistry | |
dc.subject.classification | Biophysics--Medical | |
dc.subject.classification | Virology | |
dc.title | Metabolomics comparison between Delta and Omicron-infected individuals | |
dc.type | master thesis | |
thesis.degree.discipline | Medicine – Medical Sciences | |
thesis.degree.grantor | University of Calgary | |
thesis.degree.name | Master of Science (MSc) | |
ucalgary.thesis.accesssetbystudent | I require a thesis withhold – I need to delay the release of my thesis due to a patent application, and other reasons outlined in the link above. I have/will need to submit a thesis withhold application. |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 2.64 KB
- Format:
- Item-specific license agreed upon to submission
- Description: